Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Dcvc Bio
AddedFeb 13, 2024
UpdatedJul 22, 2026
Dcvc Bio

Dcvc Bio

Operating

VC fund, DCVC Bio, invests in early-stage computational biology startups transforming life sciences.

Location
Palo Alto, CA, US
Founded
2018
Firm
Compare
Portfolio
Employees
Website

Investments

Elo Life Systems
Elo Life Systems

Total Raised

$56.5M

Rounds

3

Series A$20.5MJanuary 2024
Series A$24.5MFebruary 2023
Totus Medicines
Totus Medicines

Total Raised

$106M

Rounds

3

Series B$66MDecember 2023
Series A$40MDecember 2021
CH4 Global
CH4 Global

Total Raised

$45M

Rounds

3

Series B$29MAugust 2023
Series A$13MOctober 2021
Radionetics Oncology
Radionetics Oncology

Total Raised

$82.5M

Rounds

2

Series A$52.5MAugust 2023
Solu Therapeutics
Solu Therapeutics

Total Raised

$31M

Rounds

1

Seed$31MAugust 2023
Chroma Medicine
Chroma Medicine

Total Raised

$260M

Rounds

3

Series B$135MMarch 2023
Verdant Robotics
Verdant Robotics

Total Raised

$58M

Rounds

3

Series A$46.5MNovember 2022
Novome Biotechnologies
Novome Biotechnologies

Total Raised

$83.1M

Rounds

6

Series B$43.5MSeptember 2022
Auron Therapeutics
Auron Therapeutics

Total Raised

$61.4M

Rounds

3

Series A$48MJuly 2022
Sabanto
Sabanto

Total Raised

$22.2M

Rounds

4

Series A$17MJuly 2022
Convertible Note$3MDecember 2020
Unlearn.AI
Unlearn.AI

Total Raised

$84.8M

Rounds

6

Series B$50MApril 2022
Series A$12MApril 2020
Creyon Bio
Creyon Bio

Total Raised

$40M

Rounds

1

Series A$40MMarch 2022
Plexium
Plexium

Total Raised

$165M

Rounds

6

Series B$102MFebruary 2022
Series A$35MJanuary 2021
GenEdit
GenEdit

Total Raised

$67.7M

Rounds

7

Series A$26MSeptember 2021
Frontier Medicines
Frontier Medicines

Total Raised

$244M

Rounds

3

Series B$88.5MJuly 2021
Stemson Therapeutics
Stemson Therapeutics

Total Raised

$22.5M

Rounds

2

Series A$15MJuly 2021
Umoja Biopharma
Umoja Biopharma

Total Raised

$263M

Rounds

3

Series A$53MNovember 2020
MycoWorks
MycoWorks

Total Raised

$187M

Rounds

7

Series B$45MOctober 2020
Orca Bio
Orca Bio

Total Raised

$192M

Rounds

3

Series D$192MJune 2020